#128: AI-driven reclassification of Multiple Sclerosis – A new way of understanding MS
Today’s article is about a groundbreaking study published in Nature Medicine in 2025:“AI-driven reclassification of multiple sclerosis progression.” It was led by an international research team including Habib Ganjgahi, Dieter Häring, Fred Lublin, Ludwig Kappos, Heinz Wiendl and many more experts. The analysis was based on data from over 8,000 patients, 118,000 clinical visits, and […]
122: Living with MS in South Africa. Insights from Advocate & MSSA Vice-Chair Christelle Taute
I’m truly honored to welcome Christelle Taute, Vice-Chair and Treasurer of the Multiple Sclerosis Society of South Africa (MSSA), to the podcast. As a passionate patient advocate, Christelle has spent years empowering others in the MS community by sharing her own journey with honesty, warmth, and resilience. Her story is a reminder that even when […]
#121: MS, TheMay50K, and mental strength – a conversation with Susanne Melanie Schmid
In this interview, Susanne Melanie Schmid shares her journey with multiple sclerosis, how she found strength in vulnerability, and what helped her push beyond limits—literally and figuratively. As part of the international TheMay50K challenge, she not only walked over 60 kilometers, but also built meaningful connections, including with MS advocates in South Africa. Susanne speaks […]
#119: Voices of Leadership. CEO of MS South Africa on Patient Support and the Future of MS Care
If you’re living with MS or care about the global MS community, it’s essential to understand that while MS is one disease, it brings very different challenges depending on where in the world you are — and South Africa is no exception. In this episode, I want to give you an honest and comprehensive look […]
#110: 10 things you should know about MRI scans for MS with neuroradiologist Prof. Mike Wattjes
Prof. Mike Wattjes ist Neuroradiologe an der Medizin. Hochschule Hannover und erklärt gut verständlich, was Du zur MRT bei MS wissen solltest.
#082: Living with neuromyelitis optica (NMO) in Denmark with Leda Bresnov
Meet NMO patient Leda Bresnov, a strong and inspiring woman who is originally from Brazil and has been living in Denmark since 1991. Leda, a wife and mother of two adult children, is overcoming the challenges of Neuromyelitis optica (NMO) and is trying to raise awareness of the disease. In this interview, Leda shares her […]
#080: B-Cell Depletion – Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi) for active RRMS and SPMS, and early PPMS
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
#078: Cladribine (Mavenclad, Leustat, Litak) for highly active MS
Cladribine (Mavenclad, Leustat, Litak) is an induction therapy the supresses the immun system and is used for highly active MS.
#076: Alemtuzumab (Lemtrada, Campath) for highly active Multiple Sclerosis
Alemtuzumab (Lemtrada, Campath) is a DMT to treat highly active MS and has long-lasting effects and potential severe side effects.
#074: S1P Modulators – Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory), Siponimod (Mayzent) for active RRMS & SPMS
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
